Some representative examples include, pelitinib, a 3-cyanoquinoline anticancer agent with irreversible EGFR inhibitory activity [66], neratinib, an EGFR inhibitor, used as an adjuvant therapy in patients with early stage breast cancer in which HER2 is overexpressed [67] and bosutinib, which is used for the treatment of chronic myelogenous leukemia [68]. Here, EGFR is linked to breast carcinoma.